Breakthrough Targeted Therapy Shows Promise for KRAS‑Mutated Pancreatic Cancer, with Virginia Cancer Specialists and NEXT Oncology Playing Key Role

Daraxonrasib, a first-in-class targeted therapy for KRAS-mutated pancreatic cancer, achieved nearly 90% disease control in Phase 1/2 trials published in NEJM, with Phase 3 confirming the benefit.